{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=38", "query": { "intervention": "Cell Therapy", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 12471, "total_pages": 1248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T17:45:36.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07284641", "title": "Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Common Variable Immunodeficiency (CVID)", "Primary Immune Regulatory Disorder", "Immune Dysregulation", "DiGeorge Syndrome", "STAT 1 Gain of Function", "STAT 3 Gain of Function", "Hypomorphic RAG1 Deficiency", "CD40 Ligand Deficiency", "Mendelian Susceptibility to Mycobacterial Disease", "GATA2 Associated Immunodeficiency", "CD40 Deficiency", "Hypomorphic RAG2 Deficiency", "Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome", "Omenn Syndrome", "Chronic Granulomatous Disease" ], "interventions": [ { "name": "Hematopoietic stem cell transplant (HSCT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 25, "start_date": "2026-05-04", "completion_date": "2031-02-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284641" }, { "nct_id": "NCT04063124", "title": "Senolytic Therapy to Modulate Progression of Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Dasatinib + Quercetin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 5, "start_date": "2020-02-14", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04063124" }, { "nct_id": "NCT00153803", "title": "Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Erlotinib (tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2005-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00153803" }, { "nct_id": "NCT05038488", "title": "Phase 2a MIB-626 vs. Placebo COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19", "Stage 1 Acute Kidney Injury" ], "interventions": [ { "name": "MIB-626", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Home Treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Metro International Biotech, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-10-26", "completion_date": "2023-08-17", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038488" }, { "nct_id": "NCT07216703", "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1023, "start_date": "2026-01-19", "completion_date": "2031-10-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216703" }, { "nct_id": "NCT00028327", "title": "Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-02", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 9, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028327" }, { "nct_id": "NCT01278927", "title": "Exercise and Stress Management Post Autologous and Allogeneic Transplant (BMT CTN 0902)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Physiological Stress" ], "interventions": [ { "name": "Exercise", "type": "BEHAVIORAL" }, { "name": "Stress Management", "type": "BEHAVIORAL" }, { "name": "Exercise and Stress Management", "type": "BEHAVIORAL" }, { "name": "Standard Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 711, "start_date": "2011-01", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 19, "location_summary": "Duarte, California • Gainesville, Florida • Tampa, Florida + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278927" }, { "nct_id": "NCT04787042", "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Carcinoma", "MSI-High" ], "interventions": [ { "name": "ST-067", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Simcha IL-18, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2021-08-06", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04787042" }, { "nct_id": "NCT03774654", "title": "CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Small Lymphocytic Lymphoma", "Relapsed Adult ALL", "Relapsed CLL", "Relapsed Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CD19.CAR-aNKT cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Years to 75 Years" }, "enrollment_count": 13, "start_date": "2020-04-14", "completion_date": "2040-05-05", "has_results": true, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03774654" }, { "nct_id": "NCT04267120", "title": "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Research blood collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-07-29", "completion_date": "2024-09-01", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-27T17:45:36.910Z", "location_count": 2, "location_summary": "Palo Alto, California • St Louis, Missouri", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267120" } ] }